News - CRISPR Therapeutics
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
Home | CRISPR Therapeutics
First-Ever Approved CRISPR-Based Therapy. CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex …
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan ...
5 days ago · CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion …
CRISPR Therapeutics to Present at the Guggenheim Inaugural …
Nov 7, 2024 · CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion …
CRISPR Therapeutics Highlights Strategic… | CRISPR Therapeutics
Jan 8, 2024 · CRISPR Therapeutics continues to advance a Phase 1 clinical trial for CTX211 for the treatment of Type 1 Diabetes (T1D). CRISPR Therapeutics remains committed to its goal …
CRISPR Therapeutics Proposes New Appointment to the Board of …
6 days ago · ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating …
CRISPR Therapeutics
May 9, 2024 · CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy …
CRISPR Therapeutics Presents Data at the 2024… | CRISPR …
Dec 9, 2024 · CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion …
CRISPR Therapeutics Provides Business Update… | CRISPR …
Nov 5, 2024 · CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results-CASGEVY™ approved for the treatment of patients 12 years of age and …
Press Releases | CRISPR Therapeutics
Press Releases | CRISPR Therapeutics